ACAD
35.23
+0.33
+0.95%
AEMD
4.869
+0.139
+2.939%
APRI
0.451
+0.028
+6.6272%
ARNA
1.63
0.00
0.00%
ATEC
0.206
+0.011
+5.5441%
CNAT
2.24
0.00
0.00%
CRXM
0.165
-0.015
-8.129%
CYTX
3.089
+0.159
+5.4130%
DXCM
65.34
+0.37
+0.57%
GNMK
7.11
+0.24
+3.49%
HALO
10.07
+0.37
+3.81%
ILMN
143.74
+0.26
+0.18%
INNV
0.279
+0.019
+7.308%
INO
11.15
+0.02
+0.18%
ISCO
2.22
-0.08
-3.48%
ISIS
57.56
0.00
0.00%
LGND
122.56
+1.81
+1.50%
LPTN
0.18
-0.01
-7.22%
MBVX
0.6
-0.032
-5.0040%
MEIP
1.42
+0.03
+2.16%
MNOV
6.685
-0.025
-0.373%
MRTX
17.89
+0.41
+2.35%
MSTX
0.34
+0.03
+11.29%
NBIX
46.56
-2.21
-4.53%
NUVA
53.675
-0.475
-0.877%
ONCS
1.64
+0.01
+0.61%
ONVO
2.78
+0.03
+1.09%
OREX
0.417
-0.009
-2.1831%
OTIC
14.46
+0.78
+5.70%
QDEL
16.505
+0.115
+0.702%
RCPT
231.96
0.00
0.00%
RGLS
5.9
+0.05
+0.85%
RMD
57.8
-0.33
-0.57%
SPHS
0.931
+0.031
+3.4111%
SRNE
6.64
+0.12
+1.84%
TROV
5.37
+0.08
+1.51%
VICL
0.408
+0.018
+4.589%
VOLC
18
0.00
0.00%
ZGNX
10.19
+0.13
+1.29%
ACAD
35.23
+0.33
+0.95%
AEMD
4.869
+0.139
+2.939%
APRI
0.451
+0.028
+6.6272%
ARNA
1.63
0.00
0.00%
ATEC
0.206
+0.011
+5.5441%
CNAT
2.24
0.00
0.00%
CRXM
0.165
-0.015
-8.129%
CYTX
3.089
+0.159
+5.4130%
DXCM
65.34
+0.37
+0.57%
GNMK
7.11
+0.24
+3.49%
HALO
10.07
+0.37
+3.81%
ILMN
143.74
+0.26
+0.18%
INNV
0.279
+0.019
+7.308%
INO
11.15
+0.02
+0.18%
ISCO
2.22
-0.08
-3.48%
ISIS
57.56
0.00
0.00%
LGND
122.56
+1.81
+1.50%
LPTN
0.18
-0.01
-7.22%
MBVX
0.6
-0.032
-5.0040%
MEIP
1.42
+0.03
+2.16%
MNOV
6.685
-0.025
-0.373%
MRTX
17.89
+0.41
+2.35%
MSTX
0.34
+0.03
+11.29%
NBIX
46.56
-2.21
-4.53%
NUVA
53.675
-0.475
-0.877%
ONCS
1.64
+0.01
+0.61%
ONVO
2.78
+0.03
+1.09%
OREX
0.417
-0.009
-2.1831%
OTIC
14.46
+0.78
+5.70%
QDEL
16.505
+0.115
+0.702%
RCPT
231.96
0.00
0.00%
RGLS
5.9
+0.05
+0.85%
RMD
57.8
-0.33
-0.57%
SPHS
0.931
+0.031
+3.4111%
SRNE
6.64
+0.12
+1.84%
TROV
5.37
+0.08
+1.51%
VICL
0.408
+0.018
+4.589%
VOLC
18
0.00
0.00%
ZGNX
10.19
+0.13
+1.29%
Home » Archive by Category

Xconomy

The Biotech Roundup: Immunotherapy Ups And Downs, Gene Deals & More

May 20, 2016 – 3:30 am

A quick housekeeping note: Starting this week, we are combining our East Coast and West Coast biotech roundups into a single weekly post that will also include highlights from our other cities and…

[[Click headline to continue reading.]]

Biogen Turns To UPenn Gene Therapy Pioneers in Wide-Ranging Alliance

May 16, 2016 – 3:55 am

Even though it recently decided to unload a gene therapy for hemophilia into a yet-to-be-named spin-out company, Biogen, one of biotech’s most risk-taking firms, is doubling down on gene…

[[Click headline to continue reading.]]

White House Wants to Spend $121M on National Microbiome Initiative

May 13, 2016 – 12:35 pm

The Obama administration announced this morning a public-private initiative to study the collections of microorganisms that live on or in humans and practically everywhere else on Earth. More than…

[[Click headline to continue reading.]]

MGH Goes Epic: What I Learned in the Trenches

May 10, 2016 – 5:45 am

On April 2 at Massachusetts General Hospital (MGH), the green charts went away. Every morning around 6:30 am since starting residency, my co-interns and I had frantically scrambled around the halls…

[[Click headline to continue reading.]]

Across The Board: Ideas To Narrow Biotech’s Gender Gap

May 10, 2016 – 3:30 am

The evidence is piling up. Companies with more women in charge are better businesses. So why are so many biotechs still led mainly by men? Saira Ramasastry, a former Merrill Lynch analyst, is now a…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Acadia, Medivation, Verily, and More

May 6, 2016 – 5:40 am

Just a few weeks ago, the Silicon Valley tech entrepreneur and philanthropist Sean Parker committed $250 million of his Napster and Facebook fortune to a massive effort to accelerate ways to boost…

[[Click headline to continue reading.]]

More than a Matter of Appearances: Pharma’s Existential PR Problem

May 5, 2016 – 2:40 am

When President Obama forced Pfizer to scrap its proposed $160 billion merger with Allergan, the industry as well as the company emerged as losers in the eyes of the public, despite Pfizer’s credible…

[[Click headline to continue reading.]]

Down to Wire on Napa Summit—Get Your Invite to Our May 16-17 Event

May 4, 2016 – 9:16 am

It’s getting close to the last call for Xconomy’s invitation-only Napa Summit. We have a star-studded lineup. But there are only a few tickets and hotel rooms left, and the May 16-17 event is coming…

[[Click headline to continue reading.]]

A Vision for Boosting the Life Sciences in San Diego and Beyond

May 4, 2016 – 2:40 am

The life sciences industry represents a vital piece of San Diego’s innovation economy, contributing $31.8 billion each year in local economic impact—more than defense or even tourism, according…

[[Click headline to continue reading.]]

One Year After Gaffe, Acadia Gains FDA Nod For Parkinson’s Drug

April 29, 2016 – 5:58 pm

Last year’s shakeup and mea culpa at San Diego’s Acadia Pharmaceuticals (NASDAQ: ACAD) has paid off. The FDA said late today it has approved Acadia’s pimavanserin (Nuplazid), a…

[[Click headline to continue reading.]]